NasdaqGM - Delayed Quote USD
NewAmsterdam Pharma Company N.V. (NAMS)
21.03
+0.53
+(2.59%)
At close: June 12 at 4:00:00 PM EDT
Research Analysis
Earnings Estimate
| Currency in EUR | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 10 | 10 |
| Avg. Estimate | -0.43 | -0.42 | -1.61 | -1.84 |
| Low Estimate | -0.55 | -0.56 | -1.99 | -2.6 |
| High Estimate | -0.26 | -0.15 | -1.31 | -1.41 |
| Year Ago EPS | -0.38 | -0.16 | -2.44 | -1.61 |
Revenue Estimate
| Currency in EUR | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 11 |
| Avg. Estimate | 1.4M | 3.79M | 14.96M | 12.05M |
| Low Estimate | -- | -- | 2.59M | -- |
| High Estimate | 5.12M | 17.74M | 24.83M | 50.68M |
| Year Ago Sales | 2.08M | 27.13M | 43.39M | 14.96M |
| Sales Growth (year/est) | -32.75% | -86.03% | -65.52% | -19.49% |
Earnings History
| Currency in EUR | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.52 | -0.45 | -0.47 | -0.44 |
| EPS Actual | -0.38 | -0.16 | -0.9 | -0.3 |
| Difference | 0.15 | 0.28 | -0.44 | 0.13 |
| Surprise % | 28.19% | 63.30% | -94.02% | 30.90% |
EPS Trend
| Currency in EUR | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.43 | -0.42 | -1.61 | -1.84 |
| 7 Days Ago | -0.43 | -0.42 | -1.6 | -1.77 |
| 30 Days Ago | -0.43 | -0.42 | -1.61 | -1.75 |
| 60 Days Ago | -0.42 | -0.43 | -1.73 | -1.74 |
| 90 Days Ago | -0.42 | -0.44 | -1.73 | -1.74 |
EPS Revisions
| Currency in EUR | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 2 | 2 |
| Up Last 30 Days | 5 | 5 | 5 | 3 |
| Down Last 7 Days | 1 | 1 | 1 | 1 |
| Down Last 30 Days | 2 | 2 | 2 | 4 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NAMS | -14.25% | -152.46% | 33.87% | -14.10% |
| S&P 500 | 13.13% | 2.45% | 7.55% | 14.06% |
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 6/12/2025 |
| Initiated | Stifel: Buy | 6/10/2025 |
| Maintains | Needham: Buy to Buy | 5/8/2025 |
| Reiterates | Needham: Buy to Buy | 4/8/2025 |
| Maintains | Scotiabank: Sector Outperform to Sector Outperform | 2/27/2025 |
| Maintains | Needham: Buy to Buy | 2/27/2025 |
Related Tickers
LEGN Legend Biotech Corporation
37.91
+3.61%
NKTR Nektar Therapeutics
8.76
-8.27%
INSM Insmed Incorporated
96.88
-1.12%
RNA Avidity Biosciences, Inc.
32.14
+0.41%
VERA Vera Therapeutics, Inc.
22.52
+1.90%
MTSR Metsera, Inc.
34.58
+4.60%
ZLAB Zai Lab Limited
43.03
+3.94%
AKRO Akero Therapeutics, Inc.
53.56
+1.14%
LYEL Lyell Immunopharma, Inc.
9.74
+3.51%
APGE Apogee Therapeutics, Inc.
41.86
-1.37%